Target Metabolome Profiling-Based Machine Learning as a Diagnostic Approach for Cardiovascular Diseases in Adults.

acylcarnitines amino acids cardiovascular disorders coronary heart disease hypertension machine learning metabolites methylarginines translational medicine tryptophan catabolism

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
27 Nov 2022
Historique:
received: 25 10 2022
revised: 18 11 2022
accepted: 24 11 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

Metabolomics is a promising technology for the application of translational medicine to cardiovascular risk. Here, we applied a liquid chromatography/tandem mass spectrometry approach to explore the associations between plasma concentrations of amino acids, methylarginines, acylcarnitines, and tryptophan catabolism metabolites and cardiometabolic risk factors in patients diagnosed with arterial hypertension (HTA) (n = 61), coronary artery disease (CAD) (n = 48), and non-cardiovascular disease (CVD) individuals (n = 27). In total, almost all significantly different acylcarnitines, amino acids, methylarginines, and intermediates of the kynurenic and indolic tryptophan conversion pathways presented increased (p < 0.05) in concentration levels during the progression of CVD, indicating an association of inflammation, mitochondrial imbalance, and oxidative stress with early stages of CVD. Additionally, the random forest algorithm was found to have the highest prediction power in multiclass and binary classification patients with CAD, HTA, and non-CVD individuals and globally between CVD and non-CVD individuals (accuracy equal to 0.80 and 0.91, respectively). Thus, the present study provided a complex approach for the risk stratification of patients with CAD, patients with HTA, and non-CVD individuals using targeted metabolomics profiling.

Identifiants

pubmed: 36557222
pii: metabo12121185
doi: 10.3390/metabo12121185
pmc: PMC9781191
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 075-15-2022-304

Références

Am J Physiol Regul Integr Comp Physiol. 2012 Jul 15;303(2):R135-43
pubmed: 22592557
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
Circulation. 2015 Mar 3;131(9):774-85
pubmed: 25573147
Front Endocrinol (Lausanne). 2020 May 05;11:212
pubmed: 32431666
Atherosclerosis. 2014 Feb;232(2):260-4
pubmed: 24468136
Cell Metab. 2017 Jan 10;25(1):43-56
pubmed: 28094011
Eur J Echocardiogr. 2009 Mar;10(2):165-93
pubmed: 19270053
J Nutr. 2017 Mar;147(3):314-322
pubmed: 28179491
Lab Med. 2020 Nov 2;51(6):566-573
pubmed: 32161964
Atherosclerosis. 2015 Mar;239(1):61-6
pubmed: 25576847
J Hypertens. 2014 Jun;32(6):1159-69
pubmed: 24675680
Rambam Maimonides Med J. 2018 Jul 30;9(3):
pubmed: 29944113
Cell Metab. 2017 Feb 7;25(2):374-385
pubmed: 28178567
Cell Metab. 2012 May 2;15(5):606-14
pubmed: 22560213
J Clin Endocrinol Metab. 2021 Nov 19;106(12):3448-3454
pubmed: 34346487
BMC Cardiovasc Disord. 2007 Jul 13;7:20
pubmed: 17629908
Circ Cardiovasc Genet. 2017 Apr;10(2):
pubmed: 28360086
Science. 2012 May 25;336(6084):990-1
pubmed: 22628644
Circ Cardiovasc Genet. 2010 Apr;3(2):207-14
pubmed: 20173117
J Pharm Biomed Anal. 2017 May 10;138:118-125
pubmed: 28192719
Biomed Res Int. 2015;2015:354671
pubmed: 26090402
Clin Cornerstone. 2007;8(3):11-28
pubmed: 18452839
PLoS One. 2012;7(4):e33308
pubmed: 22485140
Biomolecules. 2022 Feb 23;12(3):
pubmed: 35327546
Am J Physiol Cell Physiol. 2007 Nov;293(5):C1679-86
pubmed: 17881609
Am J Clin Nutr. 2016 Jun;103(6):1408-16
pubmed: 27099249
Hamostaseologie. 2015;35(2):128-36
pubmed: 25599530
PLoS One. 2015 Aug 10;10(8):e0135228
pubmed: 26258408
J Hum Hypertens. 2002 Mar;16 Suppl 1:S61-3
pubmed: 11986897
Circ Genom Precis Med. 2018 Apr;11(4):e002157
pubmed: 29572205
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Circulation. 2009 Mar 31;119(12):1592-600
pubmed: 19289633
PLoS One. 2018 Feb 21;13(2):e0193138
pubmed: 29466466
Clin Pharmacokinet. 2012 Sep 1;51(9):553-72
pubmed: 22804748
Metabolomics. 2020 Jun 17;16(7):74
pubmed: 32556743
J Am Coll Cardiol. 2016 Dec 27;68(25):2850-2870
pubmed: 28007146
Endocr Pract. 2011 Mar-Apr;17(2):287-302
pubmed: 21474421
Eur Heart J. 2019 Sep 7;40(34):2883-2896
pubmed: 31102408
J Am Heart Assoc. 2017 Feb 3;6(2):
pubmed: 28159823
Eur Heart J. 2013 Jul;34(26):1982-9
pubmed: 23242195
Clin Chim Acta. 2020 Aug;507:250-256
pubmed: 32376321
Int J Mol Sci. 2021 Sep 14;22(18):
pubmed: 34576067
J Clin Invest. 2014 Oct;124(10):4204-11
pubmed: 25271725
Am Heart J. 1991 Apr;121(4 Pt 1):1244-63
pubmed: 2008853
Curr Med Chem. 2019;26(1):46-59
pubmed: 28990507
J Biol Chem. 2010 Apr 9;285(15):11348-56
pubmed: 20093359
Biochem Med. 1982 Aug;28(1):16-31
pubmed: 6816224

Auteurs

Natalia E Moskaleva (NE)

World-Class Research Center Digital Biodesign and Personalized Healthcare, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Ksenia M Shestakova (KM)

World-Class Research Center Digital Biodesign and Personalized Healthcare, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Alexey V Kukharenko (AV)

Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University, 119435 Moscow, Russia.

Pavel A Markin (PA)

World-Class Research Center Digital Biodesign and Personalized Healthcare, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Maria V Kozhevnikova (MV)

Hospital Therapy N°1 Department of the N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University, 119992 Moscow, Russia.

Ekaterina O Korobkova (EO)

Hospital Therapy N°1 Department of the N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University, 119992 Moscow, Russia.

Alex Brito (A)

Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University, 119435 Moscow, Russia.

Sabina N Baskhanova (SN)

World-Class Research Center Digital Biodesign and Personalized Healthcare, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Natalia V Mesonzhnik (NV)

World-Class Research Center Digital Biodesign and Personalized Healthcare, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Yuri N Belenkov (YN)

Hospital Therapy N°1 Department of the N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University, 119992 Moscow, Russia.

Natalia V Pyatigorskaya (NV)

Department of Industrial Pharmacy, Institute of Vocational Education I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Elena Tobolkina (E)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1206 Geneva, Switzerland.

Serge Rudaz (S)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1206 Geneva, Switzerland.

Svetlana A Appolonova (SA)

Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University, 119435 Moscow, Russia.
Department of Industrial Pharmacy, Institute of Vocational Education I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.

Classifications MeSH